Effectiveness and safety of apremilast in biologic‐naïve patients with moderate psoriasis treated in routine clinical practice in Greece: the APRAISAL study (original) (raw)

Journal of the European Academy of Dermatology and Venereology, 2021

Ioanna LefakiIoanna Lefaki

Abstract

Apremilast is an oral phosphodiesterase‐4 inhibitor indicated for patients with moderate‐to‐severe chronic plaque psoriasis and active psoriatic arthritis.

Ioanna Lefaki hasn't uploaded this paper.

Let Ioanna know you want this paper to be uploaded.

Ask for this paper to be uploaded.